



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 20 AUG 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed *A. B. Jones*

Dated 6 August 2004



Patents Form 1/77

Patents Act 1977
(Rule 16)



1/77

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1.	Your reference	44.95.81800		
2.	Patent application number (The Patent Office will fill in this part)	0317269.9	24JUL03 E824907-10 D00027 _P01/7700 0.00-0317269.9	
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	A-Viral asa Strandveien 50 N-1366 Lysaker Norway		
	Patents ADP number (if you know it)	8679409001		
	If the applicant is a corporate body, give country/state of incorporation	Norway		
4.	Title of the invention	Compounds		
5.	Name of your agent (if you have one)	Frank B. Dehn & Co.		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
	Patents ADP number (if you know it)	166001 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	21
Claim(s)	2
Abstract	-
Drawing(s)	2 + 2

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	

11.	I/We request the grant of a patent on the basis of this
	Signature <u>Frank B. Behr</u> Date 23 July 2003
12. Name and daytime telephone number of person to contact in the United Kingdom	Julian Cockbain 020 7206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Compounds

The present invention relates to certain substituted 4-hydroxyoxyphenbutazone compounds and the use thereof in therapy. More particularly, the present invention relates to such compounds and their use as anti-inflammatory, anti-viral and immunomodulatory agents.


The cyclic pyrazolidine dione compounds phenbutazone, oxyphenbutazone and 4-hydroxy oxyphenbutazone are known or suggested as having anti-inflammatory, antiviral and/or immunomodulatory properties.

15



Phenbutazone (PB)


20



Oxyphenbutazone (OPB)

25

30



4-Hydroxy OPB (4OH-OPB)


35

Many derivatives of these pyrazole based structures have

been investigated, including derivatives (e.g. US-A-3968219), and prodrugs (e.g. US-A-4117232, US-A-3957803, US-A-4169147, US-A-4036845 and US-A-4139709). The principal work on those with biological activity has, however, related to varying the makeup of and substituents on the central pyrazolidine core.

The present inventors have now, unexpectedly, established that a new class of related compounds exists in which at least one aromatic ring is substituted with at least one thiol.

In a first aspect, the present invention therefore provides a compound of the formula I, or a salt thereof




wherein R₁ is OH, SH, O-alkyl, S-alkyl, O-acyl or S-acyl; R₂ is hydrogen or more preferably an C₁-C₁₀ organic group attached by a carbon atom, e.g. an optionally substituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl or aralkenyl group; X is H, O, OO, S or SS; R₃ is absent (where X=H), is hydrogen or is a hydroxyl or thiol protecting group (e.g. a, preferably C₂-C₇, acyl, or alkaryl group, such as an acetyl or benzyl group), R₄ is a hetero- or preferably homo-cyclic aryl group, optionally substituted with a further group R₅ (e.g. with an alkyl, alkenyl or alkynyl group, OH, O-alkyl, thio, thioalkyl, halo, or primary, secondary, tertiary or quaternary amino group); one Y group is S and the other is either H (in which case only one R₆ group is present)

or S; and R_6 is (independently, where 2 R_6 groups are present) an organic group of molecular weight up to around 500 amu, such as a substituted or unsubstituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl, alkyl ester, alkyl amide, alkyl acid, polyol, sugar, oligo(alkylamide), oligo(alkylester), or oligopeptide group. Where more than one R_6 group is present, these may be the same or different.


The present inventors have also established that compounds of the invention may be conveniently prepared by the reaction between thiols and certain well known starting materials.

In a further aspect, the present invention therefore provides a method for the synthesis of a compound of the invention by reaction of a thiol (R_6 -SH) with a starting material of formula II



Wherein R_1 , R_2 , R_3 , R_4 and X are as herein described, or protected derivatives or precursors thereof. Such starting materials are typically oxyphenbutazones or 4-hydroxy-oxyphenbutazones and are synthesised by methods described herein and by methods known in the art, such as from WO 01/00585 and the references cited therein. The disclosure contained in this document and in all references cited herein is hereby incorporated herein by reference.

Specifically, 4-hydroxyoxyphenbutazones may be synthesised from oxyphenbutazones by oxidation of corresponding compounds in which the R_3X position is occupied by hydrogen; from other 4-OH OPBs by reaction of corresponding compounds in which R_3X is HX with hydroxy or thiol protecting groups to introduce non-hydrogen R_3 group, or by condensation of a hydrazine compound with an optionally protected 2-hydroxy-propane dioic acid halide, ester or similar compound, e.g.



10

wherein R_1-R_4 and X are as defined above for the starting materials and the groups L are leaving groups such as halides etc. Where X is H, oxyphenbutazones will result, which may be converted to 4-OH OPBs as described above. Where X is O, 4-OH OPBs will be formed directly.

As will be readily appreciated, the hydrazines may be prepared by hydrogenation of the corresponding diarylazo compounds (since R_4 is aryl), which in turn can be synthesised from simple aromatic nitro compounds in the presence of $LiAlH_4$.

The thiol molecule may be represented by R_6-SH , where R_6 is as defined above, a protected equivalent or a precursor thereof. Preferred R_6 groups for reacting to form the molecules of the invention will be the preferred R_6 groups indicated above.

In a further aspect, the present invention provides a

compound obtained or obtainable by reaction of a thiol
(R₆-SH as defined herein) with starting material of
formula II as defined herein. Preferably, such
compounds are obtainable by reaction of a preferred
5 starting material with a preferred thiol as defined
herein.

The present inventors have further, unexpectedly,
established that compounds of the present invention have
10 considerable utility as modulators of inflammatory and
immune reactions within the body and in the treatment of
certain conditions, particularly viral, inflammatory,
allergic and autoimmune conditions. The compounds of
the present invention may also provide a "tonic" effect
15 in subjects suffering from fatigue, lethargy or the
effects of aging, whether or not any direct,
identifiable, cause of these symptoms is evident.

In a further aspect, the present invention therefore
20 provides a method of treatment of a mammalian
(preferably human) subject comprising administering a
compound of formula I or a salt thereof as defined
herein. In a preferred embodiment, the present
invention provides a method of treatment of a viral,
25 inflammatory, allergic or autoimmune condition
(particularly disease) or of the symptoms of fatigue,
lethargy or old age by administration of at least one
compound of the present invention. Preferably, the
compound will be a preferred compound, as described
30 herein.

In a further aspect the present invention provides a
compound of formula I or a salt thereof as defined
herein for use in therapy. Preferably, the compound
35 will be a preferred compound as described herein.


In a still further aspect, the present invention

provides the use of a compound of formula I or a salt thereof as defined herein in the manufacture of a medicament. Preferably, this will be a medicament for the treatment of a viral, inflammatory, allergic or autoimmune condition (particularly disease) or of the symptoms of fatigue, lethargy or old age. Preferably, the compound will be a preferred compound as described herein.

Compounds of the present invention may be usefully administered in the form of a pharmaceutical composition, particularly for the treatment of disease. Alternatively, the compounds of the present invention may be taken in the form of an "functional food", a supplement or as a food or beverage fortification, particularly where a "tonic" effect in the reduction of the symptoms of fatigue, lethargy or old age or a general boost to the immune system is desirable.

In a yet still further aspect, the present invention therefore provides a pharmaceutical composition comprising a compound of formula I or a salt thereof as defined herein and at least one pharmaceutically acceptable excipient, carrier or diluent. The invention also provides a functional or fortified food comprising a compound of formula I or a salt thereof formulated in an edible food or beverage.

Preferred compounds of the invention are of formula III, and salts thereof;



wherein Y, R₂, R₃ and R₆ are as described above and R₅ is
is an alkyl, alkenyl or alkynyl group (such as those
listed infra for R₂), an OH, O-alkyl, O-acyl, SH, S-
alkyl, S-acyl, halo, or primary, secondary, tertiary or
5 quaternary amino group. Preferred R₅ groups are
hydrogen, OH and O-acyl (e.g O-acetyl). Most preferred
are hydrogen, OH and O-acetyl.


In the compounds and starting materials of the
10 invention, R₂ is preferably a C₁ to C₆ alkyl, alkenyl, or
alkynyl group, e.g. a methyl, ethyl, ethylenyl,
acetylenyl, n-propyl, i-propyl, prop-1-enyl, prop-2-
enyl, n-butyl, i-butyl, s-butyl, t-butyl, but-1-enyl,
but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-
15 prop-2-enyl, 2-methyl-prop-1-enyl, 2-methyl-prop-2-enyl,
n-pentyl, i-pentyl etc. More preferably R₂ is C₂ to C₆
alkyl, particularly n-butyl, i-butyl, s-butyl or t-
butyl. The most preferred R₂ group is n-butyl.

20 R₃ in the compounds and starting materials described
herein is preferably hydrogen or a metabolically labile
protecting group which yields a physiologically
tolerable byproduct. Suitable protecting groups are
acyl groups, particularly acetyl, propanoyl,
25 methylpropanoyl or n-butanoyl. Many additional OH and
SH protecting groups are however known (see e.g. Greene,
"protective groups in organic synthesis", Wiley
Interscience, NY, 1981) and these may be of value as
products, or particularly as intermediates. Most
30 preferred R₃ groups are hydrogen and acetyl.

In the compounds present invention, one Y-R₆ group may be
hydrogen but at least one (and preferably both) is a
thiol group substituted with an R₆ group, where R₆ is a
35 targeting moiety or a small (esp MW < 500) organic group
having at least two functional groups selected from
esters, amides, carboxylic acids, hydroxyl groups and


amines. Where two R_6 groups are present, these may be the same or different. Preferably, R_6 is an oligo ester or oligo peptide with at least one free acid and/or amine group. Examples of such groups include specific binding peptides such as antibody fragments. More preferably, at least one $Y-R_6$ group is a 1-5 residue oligo peptide. Most preferably, at least one $Y-R_6$ group is glutathione. That is to say, both $Y-R_6$ groups may be glutathione, or one may be glutathione and the other hydrogen.

The most preferred compound of the present invention is of formula IV or a salt thereof;



wherein R_5 is hydrogen or OH and at least one R_6-Y group is a glutathione moiety attached via the sulphur atom thereof.

25 Preferred methods for the synthesis of compounds of formula I comprise condensation of thiols (R_6-SH) with starting materials of formula (V);



wherein the groups R_6 , R_2 , R_3 and R_5 are as described

above and are preferably the preferred groups described above. In the most preferred starting material, R_1 is OH, R_2 is C_4H_9 (preferably n-butyl), R_3 is H and R_5 is H or OH. Preferred thiols are those of formula R_6 -SH where
5 R_6 is a preferred R_6 group as defined herein.

The condensation of the starting materials with a thiol may be carried out in aqueous solution, particularly in neutral or slightly basic aqueous solution at
10 temperatures between 0°C and 100°C , preferably between 20°C and 60°C for a period of 30 seconds to 4 hours, preferably 4 minutes to 1 hour, most preferably 10 to 45 minutes. In some cases the compound of formula I
15 resulting from the ring-opening reaction will be labile to hydrolysis but will generally have a longer lifetime than its rate of formation from the starting material. In such cases, the reaction time will preferably be shorter than the half-life of the product under the conditions of the reaction.

20 The progress of the ring-opening reaction will be conveniently followed by techniques well known in the field of organic chemistry such as Nuclear Magnetic Resonance (NMR) spectroscopy, Infra-Red (IR)
25 spectroscopy and/or mass spectrometry.

Medical conditions suitable for treatment, prevention or control by administration of the compounds, formulations, compositions or medicaments of the present
30 invention include viral, autoimmune, inflammatory and allergic conditions including those which are secondary to other conditions and those having a viral, autoimmune, inflammatory or allergic component. Examples of immune, autoimmune, inflammatory and
35 allergic conditions or conditions having a contribution from these mechanisms include Addison's disease, allergic conditions such as hay fever, food (e.g. nut,

wheat or seafood) allergies or skin allergies, Alzheimer's disease, amyloidosis, (such as that resulting from conditions such as arthritis or tuberculosis), ankylosing spondylitis, asthma, antiplastic anemia, Behçet's disease, Bechterew's disease, Cogan's syndrome, Crohn's disease, dermatomyositis, diabetes mellitus, eczema, glandular disorders (such as diabetes, especially type II, and hypo- or hyper-thyroidism), glomerulonephritis, haemolytic anemia, Hepatitis, Huntington's disease, inflammatory bowel diseases such as irritable bowel syndrome, immune suppression (such as due to infection with HIV, compromised bone marrow function, treatment with cytotoxic chemotherapeutic agents etc.), liver diseases such as autoimmune hepatitis or primary biliary cirrhosis, lung diseases such as interstitial lung disease, lupus erythematosus, Morbus Reiter, neoplastic disease (such as benign or particularly malignant neoplasms e.g. cancer (sarcoma or carcinoma), leukemia etc.), neurological disorders such as multiple sclerosis or myasthenia gravis, inflammatory or autoimmune ocular disorders such as scleritis or uveitis, post-operative ocular inflammation, or resulting from Behçet's disease, osteoarthritis, Parkinson's disease, pemphigus, polyglandular deficiency, polymyositis, pernicious anemia, psoriasis, rheumatoid arthritis and other rheumatic disorders (such as Besnier's rheumatism, rheumatic fever, lumbago, or Poncet's rheumatism), sarcoidosis, scleroderma, Sjögren's syndrome, testicular failure, thrombocytopenic purpura, tissue rejection and prevention thereof, ulcerative colitis and Wegner's granulomatosis. Examples of viruses and viral conditions which may be treated, prevented and controlled include viral infections of CD4 cells (e.g. HIV-1, HIV-2, HTLV-I, HTLV-II and herpes viruses), togaviridae, reoviridae, picornaviridae, hantaviridae, orthomyxoviridae, paramyxoviridae, mononegaviralis,

viral hepatitis, haemorrhagic fever, flaviviridea, viral encephalitis, coronaviridea, calciviridea, adenoviridea, papoviridea, arboviridea, pox virus, rhabdoviridea, and arenaviridea.

5

The thiol derivatised compounds of the present invention are advantageous over known compounds because the positions containing thiol substituents are not available for reaction with thiols in vivo. Consumption of thiols such as glutathione can damage or kill cells and thus, the compounds may show lower toxicity and/or fewer side effects than known compounds.

10

Where the compounds, compositions or medicaments of the invention are administered to combat primary or secondary diseases, these may be in combination with other active agents, either as a combined formulation or as separate formulations administered simultaneously or sequentially. In particular, where the compositions of the invention are administered to combat a secondary disease, this will typically be simultaneously with, or following, treatment for the primary condition. For example, the compositions of the present invention may be administered in combination with antiviral agents (such as nucleoside analogues) in order to combat the viral disease and provide improved quality of life for the subject.

15

20

25

Compounds of the present invention may be formulated as pharmaceuticals by methods well known in the art. These formulations will typically be oral formulation such as tablets, coated tablets (such as controlled release tablets), capsules, suspensions, solutions, syrups, powders, or emulsions but may be formulations for inhalation (such as powders or aerosols), transdermal absorption (such as patches) or for parenteral (e.g subcutaneous, intramuscular or intravenous) ocular or

30

35

rectal administration in the form of, for example, sterile saline solutions, drops or suppositories. Where the treatment is to be, for example, to reduce the inflammatory reactions relating to asthma, inhalable preparations will be most suitable and for some allergic conditions such as hay fever, nasal sprays may be most effective. Equally, topical preparations such as drops, creams or gels will be more suitable for ocular conditions or localised skin conditions.

The compounds of formula I and salts thereof may be formulated with conventional pharmaceutical carriers, dilluents and/or excipients such as aqueous carriers (e.g. water for injections), binders, fillers, stabilizers, osmolality adjusting agents, effervescing agents, pH buffers and modifiers, viscosity modifiers, sweeteners, lubricants, emulsifiers, flavours, coating agents (e.g. gastric juice resistant coatings) etc.

The dosage of the compounds of formula I or salts thereof administered to a subject will be dependent upon the species, size, maturity, health and condition of the subject, upon the severity of the condition and upon the formulation chosen. Inhalable or intravenous formulations, for example, may deliver a larger proportion of the active agent to the subject than oral formulations and topical treatment will typically require lower doses than systemic treatment. Generally, doses will be in the range of 0.05 to 2000 mg/day, more typically 0.2 to 1000 mg/day, especially 0.5 to 200 mg/day. Administration will typically be once, twice, three or four times per day but may more or less often (e.g. five or six times per day, once every two or three days, or every time symptoms are detected) if appropriate. Topical treatment will typically be administered more often than systemic treatments.

Where the compounds of the present invention are administered as a tonic, such as to reduce lethargy, the symptoms of old age or to boost the immune system, they may be formulated as pharmaceuticals as above.

5 Alternatively, the compounds may be formulated as functional foods or beverages, in which situation the carriers and excipients will typically be edible food or beverage products. Such products may be processed foods for consumption hot, such as ready meals but will more
10 preferably be cold foods include spreads, jams, still or carbonated soft drinks, breads, biscuits, icecreams, chilled desserts such as yoghurts, mousses or trifles, milk or milk based drinks.

15 Where the compounds of the invention are formulated as functional foods or beverages, it will be important that the maximum dose which can be accidentally consumed by over-eating such foods is not excessive. In such cases, the dosage present in one portion of such functional
20 foods will typically be no more than 5 000 times less than the lethal dose, more preferably no more than 10 000 times less and most preferably no more than 100 000 times less than the human lethal dose.

25 Where the compounds of the invention are referred to herein as salts, these will generally be pharmaceutically acceptable salts i.e. those with physiologically tolerable counterions. Such ions include sodium, calcium, organic amines, halides
30 (especially chloride), phosphates, hydrogen carbonates etc.

Without being bound by theory, the effect of the compounds, compositions and medicaments of the invention
35 is believed in part to be the result of a stimulating and modulating effect upon certain aspects of the mammalian immune and defence systems, particularly, for

example, by enhancing macrophage activity and white blood cell (WBC) activity and count and modulating levels of the acute phase proteins (APPs) such as C-reactive protein (CRP). The "tonic" effect of the compositions may therefore be, at least partially, attributable to a "cleanup" effect, in which the body is stimulated to remove not only infectious agents but also cell debris and other unwanted matter. In addition, and in spite of their effect as WBC stimulants, the compounds of the invention show effects as inhibitors of the production of certain cytokines and of T-lymphocyte and monocyte activation and modulators of interleukins. By such a processes, the tendency for the immune system to generate unwanted inflammation both in general and as a result of encountering biological debris is reduced, as is the danger of autoimmune reaction. As a result, the subject is provided with a better quality of life and the immune system is stimulated and the body purged of some unnecessary and even detrimental antigens. This tonic effect may be applied during or following treatment for a primary disease, condition or infection, or may be an end in itself, when, for example, infection, drug treatment or the aging process has resulted in compromised immune function or a build up of unwanted, immunogenic and/or inflammatory matter in the system.

The stimulation of systems such as certain APPs is believed to induce a cleanup of the system, removing cell debris that would otherwise stimulate inflammation and may present native antigens that could induce autoimmune responses. The breakdown products of host cells can also induce the death of neighbouring cells, thereby causing a cascade of cell death and inflammation. Unusually, the compounds of the present invention typically stimulate acute phase proteins without inducing significant fever and are not typically

general immune-suppressants.

Additional methods for bringing about a cleanup of biological debris include binding by certain plasma
5 proteins such as particular immunoglobulins of type M (IgMs) with specificity for the membrane phospholipids of dead (but not living) cells, b2 glycoprotein I, clusterin and serum amyloid P. The activity of these mechanisms may also be modulated by the compounds of the
10 present invention.

Diseases of collagen, such as systemic lupus, are for example believed to have a build up of cell debris as a primary cause in many cases. As a result, the compounds
15 of the present invention are highly suitable for the treatment or prevention of collagenous disease, for example in those showing symptoms of the disease or those having a predisposition due to inheritance or injury.

20 Similarly, a build up of biological debris is a particular problem in Multiple Sclerosis and may only be treated by existing agents having considerable side-effects, such as β -interferon. The compounds of the
25 present invention allow a more targeted stimulation of APP and consequent removal of debris which may be highly valuable in such cases. Cell debris is also believed to contribute to Alzheimer's, Parkinson's and Huntington's diseases.

30 The tonic effect of the compounds of the present invention in older subjects may also be explicable as a result of a cleanup mechanism. As subjects age, a greater proportion of cells suffer programmed cell death
35 due to telomere reduction and apoptosis. At the same time, the level of clean up mechanisms such as APPs and the effectiveness of the immune system typically

declines. This may lead to a build up of debris and a susceptibility of infection, these factors then leading to degenerative diseases and conditions such as heart attacks. By prophylactic treatment with the compounds of the present invention, the immune system and APP levels may be stimulated reducing the debris buildup and causing the immune system to rid the body of infections before catastrophic events such as bursting of blood vessels causes conditions such as heart attacks.

In a similar way to that seen in aging subjects, those suffering from chronic disease may experience a build up of biological debris from both host cells and infectious agents. The compounds of the present invention may be administered to speed recovery and improve quality of life in such cases. This mechanism is also suitable for speeding the recovery of any subject after events such as surgery, burns or sepsis.

The immune stimulation and cleanup effect of the compounds of the invention may be used in combination with other drugs, particularly to improve the quality of life of subjects having compromised immune function resulting from a primary condition or the treatment therefore. For example, patients suffering from HIV and related conditions may be treated with one or more antiretroviral agents in order to treat or control the disease. Examples of these include reverse transcriptase inhibitors and protease inhibitors such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, nevirapine, delavirdine, indinavir, ritonavir, nelfinavir, hydroxyurea, colchicine, AZT and 2',3'-dideoxyinosine (ddI). In combination with this treatment, the compounds, compositions or medicaments of the invention may be administered in order to purge and stimulate the patients remaining immune function.

Similarly, subjects suffering from a hyperplastic or
neoplastic disease such as cancer or leukemia may be
treated with one or more cytotoxic agents (such as
nucleoside analogues), by surgery, external beam
5 irradiation and/or radionuclide therapy. In such cases,
the immune system of the subject is generally suppressed
as a side effect of the therapy. The immune system may,
however, be boosted by administration of the compounds
of the present invention in order to provide the subject
10 with lower susceptibility to infection during and after
the primary therapy. In addition, the compounds or
compositions of the present invention may be
administered to stimulate or focus an immune response
(particularly, for example by the stimulation of
15 macrophages) against any remaining tumour cells, micro-
tumours or micro-metastases in order to provide more
complete remission of the disease. Such treatment may
be carried out during or after treatment by other
agents or interventions.

20 The compounds of the present invention may also be used
to stimulate the destruction (particularly by
macrophages/monocytes) of micro-tumours and thereby
prevent the formation or spread of neoplastic disease.
25 This will apply particularly in older subjects (see
below) or those considered as having a predisposition to
neoplastic disease (e.g. due to heredity; exposure to
predisposing chemical or physical environments, such as
carcinogens, ionising radiation, etc; previous treatment
30 for neoplastic disease; results of genetic testing etc).

In a further preferred aspect, the present invention
therefore provides a method for the treatment of a
mammalian (preferably human) subject comprising
35 administration of a compound of formula I or a salt
thereof as defined herein, in combination with another
drug and/or treatment regime. Preferably, the method is

a method for the treatment of a viral, hyperplastic or neoplastic disease, more preferably for the treatment of HIV, cancer or leukaemia. The other drug is preferably an antiviral, such as those listed herein or an
5 antineoplastic agent such as a radiopharmaceutical or chemotherapeutic (e.g. asparaginase, bleomycin, cisplatin, cladribine, cyclophosphomide, cytarabine, dacarbazine, daunorubicin, doxorubicin, etoposide, fluorouracil, hydroxyurea, mercaptopurine, mustine,
10 methotrexate, procarbazine, or vinblastine). The other treatment regime is preferably surgery and/or external beam irradiation. In this method, the compound of the present invention will typically be formulated as a pharmaceutical, either as the sole active agent or in
15 combination with at least one other drug agent and will be administered prior to or preferably consecutively with or after the other drug or treatment.

In a preferred embodiment, the invention also provides a
20 method of prophylaxis against the development of cancer or other neoplastic disease comprising administration of a compound of the invention.

Where symptoms such as fatigue or lethargy are the
25 result of old age or viral, bacterial or fungal infection or the symptoms or treatment of hyperplastic disease such as cancer, the compounds of the present invention may be administered either as a pharmaceutical, or as an additive in, for example a
30 "functional food". Where the cause is a medical condition or treatment, the compound of the invention will generally be taken in the form of a pharmaceutical. Where, however, the cause is simply the result of the general build up of unwanted debris in old age, the
35 compounds of the present invention will preferably be taken in the form of a functional food or dietary supplement for convenience and ease of compliance.

In a preferred aspect, the present invention therefore provides a method of tonic treatment of an aging mammalian (preferably human) subject, or a subject suffering from the aftereffects of infection, disease or treatment, comprising administration of a compound of formula I or a salt thereof as defined herein. Where the subject is an aging human, they will preferably be at least 60 years of age, more preferably at least 70 and most preferably at least 75. The subject may be suffering from an identifiable viral, immune-deficient, autoimmune or allergic disease or condition, or may be a generally healthy subject in these or all respects wishing for a boost in physical or mental energy or in immune function or a reduction in fatigue or lethargy. The invention also provides for the use of the compounds of the invention in the manufacture of a tonic medicament suitable for use in such methods.

The present invention will now be illustrated by the following, non-limiting examples.

Examples

¹H-NMR were recorded on a Bruker 300 MHz spectrometer with CDCl₃ as solvent. HPLC was performed with a Gynkotek pump equipped with a Symmetry C-18, 5mm, 3.9x150 mm column and a Gynkotek UVD 170S detector set at 254 nm. Gradient: 1% TFA in water/acetonitrile 70/30 to 0/100 in 8 min.

Example 1 - Synthesis of starting material - 4OH OPB

To a 1-litre round bottom flask with magnetic stirring is charged methanol (450 ml) and oxyphenbutazone hydrate (90.0 g, 0.26 mol). The solution is stirred at ambient temperature and sodium hydroxide solution (2M, 13.5 ml)

is added. Hydrogen peroxide (30%, 180 ml) is added drop wise over 10 min. The resulting clear pale yellow solution was stirred for 24 h. The resulting suspension was cooled on an ice bath for 2.5 h and the mixture
5 filtered through a glass filter and sucked dry. The light brown crystals were washed carefully on the filter with MeOH/water (1:2, 200 ml), sucked dry and washed once more with 100 ml of the same solvent mixture. The product was allowed to dry on the filter over night. The
10 crude product was then transferred to a 200 ml round bottom flask, diethyl ether (200 ml) added and the resulting suspension stirred vigorously for approximately 5 min. The mixture was filtered and sucked dry on the filter. The appearance of the product
15 was pale pink after the ether treatment. Crude yield 53 g. The ether treatment procedure was repeated once more with 150ml of ether. The now almost white material was dissolved in methanol (330 ml) to give a red solution. Water (350 ml) was charged slowly over 35 min
20 to give a white suspension. The solid was collected on a glass filter and dried in vacuo at 30°C over night to give 4-OH OPB as a pale pink solid, 31g, 35%. HPLC>98%. ¹H NMR (see Figure 1) confirms identity with reference sample.

25

Example 2 - thiol derivitisation

The 4OH-OPB of Exmample 1 was derivatised with glutathione by incubation in glutathione (GSH) solution
30 followed by purification. Conditions were chosen such that approximately equal quantities of the mono-glutathione substituted product (4OH-OPB-1GSH) and di-glutathione substituted product (4OH-OPB-2GSH) resulted.

35

Incubation

4OH-OPB (170mg) was dissolved in PBS (100ml, formulated

as below) additionally containing 1.5mM glutathione. The solution was incubated for 30 minutes at 37°C and the reaction followed by Mass Spectrometric analysis.

5 *Purification*

An analytical HPLC run (C18 reversed phase column) was performed to validate the products formed (determination by Mass Spectrometry). The 4OH-OPB-1GSH and 4OH-OPB-2GSH were then purified by loading all 100mL of the incubation mixture on a preparative column (C18, reversed phase column).

Both analytical and preparative runs were eluted with gradient eluents, running from 0% acetonitrile to 67% acetonitrile (in deionised water) in the presence of 0.1% TFA to keep the pH at 2. During the preparative run, fractions were collected (peaks) and checked for the right product by Mass Spectrometry. Finally, the identified products were dried under vacuum leaving products with ~99% purity (as judged by MS).


PBS = (phosphate buffered saline, pH 7.5)
NaCl, 8.2g; Na₂HPO₄·2H₂O, 1.9g; NaH₂PO₄·H₂O, 0.3g; Na⁺, 163, 9mM; Cl⁻, 140, 3mM; HPO₄²⁻, 10, 9mM; H₂PO₄⁻, 1, 8mM, Braun Melsungen AG.

Example 3 - Suppression of Cytokine production

Two batches of the 4OH-OPB-2GSH, as prepared in Example 2, were incubated with isolated human mononuclear cells (MNC) derived from peripheral blood from healthy volunteers. Production of the cytokines Interleukin-6 (IL6) and Granulocyte Colony-Stimulating Factor (GM-CSF) was measured. The results (shown in Figures 2 and 3) indicate that 0.5-5 µM of product is sufficient to completely block production of the measured cytokines.


Claims:

- 1) A compound of the formula I, or a salt thereof



wherein R_1 is OH, SH, O-alkyl, S-alkyl, O-acyl or S-acyl;
 R_2 is hydrogen or more preferably an C_1 - C_{10} organic group
 15 attached by a carbon atom, e.g. an optionally
 substituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl or
 aralkenyl group; X is H, O, OO, S or SS; R_3 is absent
 (where $X=H$), is hydrogen or is a hydroxyl or thiol
 protecting group (e.g. a, preferably C_2 - C_7 , acyl, or
 20 alkaryl group, such as an acetyl or benzyl group), R_4 is
 a hetero- or preferably homo-cyclic aryl group,
 optionally substituted with a further group R_5 (e.g. with
 an OH, O-alkyl, thio, thioalkyl, halo, or primary,
 secondary, tertiary or quaternary amino group); one Y
 25 group is S and the other is either H (in which case only
 one R_6 group is present) or S; and R_6 is (independently,
 where two R_6 groups are present) an organic group of
 molecular weight up to around 500 amu, such as a
 substituted or unsubstituted alkyl, alkenyl, alkynyl,
 30 alkaryl, aralkyl, alkyl ester, alkyl amide, alkyl acid,
 polyol, sugar, oligo(alkylamide), oligo(alkylester), or
 oligopeptide group.

2) A method for the synthesis of a compound of the invention by reaction of a thiol (R_6 -SH) with a starting material of formula II



Wherein R_1 , R_2 , R_3 , R_4 and X are as defined in claim 1, or protected derivatives or precursors thereof.

15 3) A method of treatment of a mammalian (preferably human) subject comprising administering a compound of formula I as defined in claim 1.

20 4) A compound of formula I as defined in claim 1 for use in therapy.

25 5) A method of tonic treatment of an aging mammalian (preferably human) subject, or a subject suffering from the aftereffects of infection, disease or treatment, comprising administration of a compound of formula I as defined in claim 1.

1/2




Figure 1




Figure 2




Figure 3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.